Startups channel feed – Endpoints News

Startups channel feed

Third Rock seeds cell therapy startup with $95M in bid to cure MS

4 years ago

A replacement for reading glasses? An RA, Versant-backed startup thinks its eyedrops could solve farsightedness

4 years ago

Michel Sadelain puts his name and new cell engineering tech behind 'agnostic' CAR-T startup chasing epigenetic antigens

4 years ago

Going after the phenomenon of 'regRNA,' Rick Young's Camp4 secures a launch round to push two programs forward

4 years ago

A Medicxi-backed startup looks to tackle treatment-resistant blood cancers, and it's going after AML first

4 years ago

A gene therapy biotech is bursting onto the scene with 12 programs in tow. An ultra-rare neuro disease is up first

4 years ago

Polaris, AbbVie, Bayer back Stuart Schreiber's hunt to turn cancer treatments into cures

4 years ago

Salvaging 'ugly fruit': After a series of protein degradation bets, Versant turns to protein stabilization platform out of Columbia

4 years ago

Almost a decade after identifying a new class of RNA, a group of scientists sparks interest from Takeda Ventures

4 years ago

Alloy and Pyxis spin out new 'company' around high-risk I/O, immunology targets

4 years ago

A new RNA startup looks to reimagine heart treatments, with eyes set on Entresto

4 years ago

HIV researcher David Ho has a new line of attack on SARS-CoV-2, and his fledgling startup is gunning for the clinic

4 years ago

Months after Novartis buyout, the old Vedere Bio team is back at it with a new pipeline and a fresh $77M

4 years ago

An OrbiMed-backed startup looks to cut excess corticosteroids with mid-stage tests for its lead drug queued up

4 years ago

Jim Wilson and Tachi Yamada are at it again — launching a 2nd-gen gene therapy company with an appetite for risk, global vision and $200M to gamble with

4 years ago

A T-cell player with backing from Roche takes next big step for BiTE drugs with 'on-off' switch to avoid toxicity

4 years ago

After going down different drug discovery paths, Genentech vets reunite at Foresite Labs to map the 'protein interactome'

4 years ago

A Third Rock-backed player charts a new course against transcription factors. Do 'switch sites' hold the magic sauce?

4 years ago

A non-opioid pain startup believes it can top the bupivacaine market — and it's thinking in terms of weeks, not days

4 years ago

With backing from Bayer, a London firm will pitch its 'hospitals at home' concept for decentralized trials

4 years ago

Can a rare immune cell offer the key to slowing down senescence? A Bay Area startup looks to find out

4 years ago

The incubator that hatched a Jennifer Doudna CRISPR startup blueprints new 'destination for life science entrepreneurship'

5 years ago

The company behind Moderna has a new RNA startup looking to disrupt drugmaking. The goal? 100 new drugs in 10 years

5 years ago

OcuWho? Star dealmaker turned aesthetics czar Brent Saunders flips back into biotech. But who’s he teaming up with now?

5 years ago

First page Previous page 45 46 474849 50 51 Next page Last page